Filing Flows › Comparisons › TBPH vs RAPP
Theravance Biopharma vs Rapport Therapeutics: TBPH and RAPP compared
Theravance Biopharma is the larger company: $20.7M of revenue in its latest quarter (Q2 2026) against $20.0M for Rapport Therapeutics (Q1 2026). Theravance Biopharma is more profitable, with an operating margin of -39.9% against -121.1%.
Where the money goes: TBPH and RAPP
Theravance Biopharma (TBPH) · Q2 2026
Theravance Biopharma, Q2 2026: revenue $20.7M (-21% year over year), operating margin -39.9%, net loss $5.9M, operating cash flow −$7.0M. The chart follows the revenue to costs, profit and cash.
Rapport Therapeutics (RAPP) · Q1 2026
Rapport Therapeutics, Q1 2026: revenue $20.0M, operating margin -121.1%, net loss $19.9M, operating cash flow −$13.1M. The chart follows the revenue to costs, profit and cash.
| Theravance Biopharma (TBPH) | Rapport Therapeutics (RAPP) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q1 2026 |
| Revenue | $20.7M | $20.0M |
| Revenue growth, Y/Y | -21% | — |
| Operating margin | -39.9% | -121.1% |
| Net earnings | −$5.9M | −$19.9M |
| Net margin | -28.5% | -99.3% |
| Operating cash flow | −$7.0M | −$13.1M |
Questions
Which is bigger, Theravance Biopharma or Rapport Therapeutics?
Theravance Biopharma is the larger company: $20.7M of revenue in its latest quarter (Q2 2026) against $20.0M for Rapport Therapeutics (Q1 2026).
Is Theravance Biopharma or Rapport Therapeutics growing faster?
Theravance Biopharma is more profitable, with an operating margin of -39.9% against -121.1%.
More: Theravance Biopharma earnings · how Theravance Biopharma makes money · Rapport Therapeutics earnings · how Rapport Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 11, 2026; 10-Q filed May 7, 2026). Fiscal quarters can end on different dates. Not investment advice.